Press "Enter" to skip to content

Seqster Raises $12 Million To Adopt Healthcare Data Interoperability Technology

Seqster PDM Inc. (“Seqster”), a pioneer of patient-centric Healthcare Data technology, has raised $12 million in a Series A round of venture capital funding. OmniHealth Holdings LLC led the round, with Takeda Digital Ventures and Anne Wojcicki, the CEO and Founder of 23andMe, also investing. Seqster’s ability to develop and improve its technology in order to meet the demand for its multi-dimensional Healthcare Data platform is bolstered by this investment.

Seqster uses proprietary technologies to connect patients with reliable, longitudinal, and detailed Healthcare Data in real-time, both at the individual level and scale. EHRs, pharmacy data, lab data, genomic data (DNA), fitness wearables data, and social determinants of health (SDOH) are all examples of this.

Ardy Arianpour, CEO and co-founder of Seqster, said, “Seqster was built on the foundation that real-time access to a patient’s complete medical history can solve major pain points across the healthcare continuum, impacting lives at scale.” He said that he is excited to have investors who are experienced operators. They certainly share the vision and mission to change the way of capturing, refining, and managing disparate data.

Tim O’Donnell, Managing Partner of OmniHealth Holdings said that Seqater is solving the biggest challenges of Healthcare. Ardy Arianpour, Dr. Xiang Li, and Dana Hosseini created Seqster in 2016 to directly answer healthcare’s fundamental issue of data silos and fragmented Healthcare Data. During the COVID-19 pandemic, automated real-time data collection is even more important, particularly in clinical trials. The Seqster platform has been used by leading biopharmaceutical companies for remote clinical trials all over the world.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *